left_arrow.svgright_arrow.svgscroll_to_top_v1.svg
house-fill__1_.svgPath_Copy_5.svg
Discovery to Clinic
Path_Copy_5.svg
Precision Medicine
Path_Copy_5.svg
Tracing Tau to Tackle Alzheimer's Disease
Tracing Tau to Tackle Alzheimer's Disease
Using multi-modal imaging and precision medicine to tackle dementia
img_20150715_HMH_AR_05074-X4.jpg
Joseph C. Masdeu, MD, PhD, studies the protein tau to understand how to prevent cognitive degeneration and tailor patient treatments based on unique personal profiles.
Share this story
Facebook.svg
Twitter.svg
LinkedIN.svg
The Houston Alzheimer Study is a TMC-wide effort to define the abnormal chemistry leading to cognitive impairment, potentially earlier in life. By sharing data across institutions and connecting the dots using artificial intelligence, we will be empowered to understand how to prevent degeneration and tailor treatments to each patient’s unique personal profile.
Joseph C. Masdeu
, MD, PhD
Graham Family Distinguished Chair for Neurological Sciences, Stanley H. Appel Department of Neurology Director, Nantz National Alzheimer Center Professor of Neurology Houston Methodist
Houston Methodist neurologist Joseph Masdeu, MD, PhD, tends to think outside the box. And he applies this skill to what may be medicine’s greatest mystery: the brain and how it works.
Shortly after arriving at Houston Methodist in 2014, Masdeu took a bold step. He reported his findings that neurodegeneration in Alzheimer’s was associated with abnormal tau, a protein that forms inside cells from the normal tau that maintains the integrity of microtubules. At the time, most Alzheimer’s experimental therapies focused on the amyloid protein. But Masdeu did not find a similar association with the amyloid protein, also found in this disorder.

In April 2019, Masdeu pushed forward with the concept that abnormal tau may spread in the brain through the normal brain highways, the white matter tracts that connect brain hubs to each other in a complex network arrangement. His study, published in 
The Journal of Nuclear Medicine
, is the first to demonstrate this concept 
in vivo
 in humans. Using sophisticated neuroimaging, Masdeu and his team, particularly Belen Pascual, PhD, combined MRI and 18F-flortaucipir PET to study tau in a rare disease that affects the language-related syntactic brain network. The anterior node of this network, in the frontal lobe, was affected first. Sick neurons found here, containing tau, contacted and "infected” neurons in the separate, but connected, posterior node in the temporal lobe. The white matter tract connecting both nodes was affected, as would be expected when the neurons in the anterior node died first.
Pascual B, Funk Q, Zanotti-Fregonara P, Pal N, Rockers E, Yu MM, Spann B, Román GC,Schulz PE, Karmonik C, Appel SH, & Masdeu JC. Multimodal 18F-AV-1451 and MRI findings in non-fluent variant primary progressive aphasia: possible insights on nodal propagation of tau protein across the syntactic network. 2019,
Journal of Nuclear Medicine
, vol. 60, no. 7.
This discovery reveals a window of opportunity for treatment, because to jump from neuron to neuron, tau appears to become extracellular
and possibly amenable to immunotherapy using antibodies that target this abnormal protein. Several pharmaceutical companies are interested in this approach: Three clinical trials are underway at the Nantz National Alzheimer Center of the Houston Methodist Stanley H. Appel Department of Neurology using anti-tau antibodies from Abbvie, Biogen and Eli Lilly.

The Nantz National Alzheimer Center also is a leading partner in the Houston Alzheimer Study, a precision medicine cohort based in the Texas Medical Center, which intends to enroll 550 participants over age 40 to explore a range of cognitive disorders using advanced imaging, chemical analysis and artificial intelligence.
Share this story
Facebook.svgTwitter.svgLinkedIN.svg
Contact Us
© 2020. Houston Methodist, Houston, TX. All rights reserved.
Privacy & Disclaimer
.